<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Nephrol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Nephrol</journal-id><journal-title-group><journal-title>BMC Nephrology</journal-title></journal-title-group><issn pub-type="epub">1471-2369</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27884120</article-id><article-id pub-id-type="pmc">5123289</article-id><article-id pub-id-type="publisher-id">405</article-id><article-id pub-id-type="doi">10.1186/s12882-016-0405-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Removal of free light chains in hemodialysis patients without multiple myeloma: a crossover comparison of three different dialyzers</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Donati</surname><given-names>Gabriele</given-names></name><address><email>gabriele.donati@aosp.bo.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Moretti</surname><given-names>Maria Ilaria</given-names></name><address><email>mariailaria.moretti@yahoo.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Baraldi</surname><given-names>Olga</given-names></name><address><email>olga.baraldi@aosp.bo.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Spazzoli</surname><given-names>Alessandra</given-names></name><address><email>alessandra.spazzoli@studio.unibo.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Capelli</surname><given-names>Irene</given-names></name><address><email>irene.capelli@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Comai</surname><given-names>Giorgia</given-names></name><address><email>giorgia.comai@aosp.bo.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Marchetti</surname><given-names>Antonio</given-names></name><address><email>antonio.marchetti4@unibo.it</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sarma</surname><given-names>Maria</given-names></name><address><email>maria.sarma@aosp.bo.it</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mancini</surname><given-names>Rita</given-names></name><address><email>rita.mancini@aosp.bo.it</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>La Manna</surname><given-names>Gaetano</given-names></name><address><phone>+390512143255</phone><email>gaetano.lamanna@unibo.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Nephrology Dialysis and Renal Transplantation Unit, S.Orsola University Hospital, Via Massarenti 9, 40138 Bologna, Italy </aff><aff id="Aff2"><label>2</label>Department of Medicine and Public Heath, University of Bologna, Bologna, Italy </aff><aff id="Aff3"><label>3</label>Central Laboratory, S.Orsola University Hospital, Bologna, Italy </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>17</volume><elocation-id>193</elocation-id><history><date date-type="received"><day>21</day><month>7</month><year>2016</year></date><date date-type="accepted"><day>15</day><month>11</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Immunoglobulin light chains are classified as middle molecule uremic toxins able to interact with B lymphocyte membranes leading to the activation of transmembrane signaling. The ensuing impairment of neutrophil function can contribute to the chronic inflammation state of uremic patients, and the increased risk of bacterial infections or vascular calcifications. The aim of this crossover observational study was to assess the difference in free light chain removal by three different hemodialysis filters in patients not affected by multiple myeloma.</p></sec><sec><title>Methods</title><p>Free light chain removal was compared in the polymethylmethacrylate (PMMA) membrane Filtryzer BK-F, the polyphenylene HFR17 filter and the conventional polysulfone filter F7HPS. Twenty chronic hemodialysis patients were enrolled: mean age was 67.7&#x02009;&#x000b1;&#x02009;17.0&#x000a0;years, M/F&#x02009;=&#x02009;14/6, dialysis vintage (months) 25.5&#x02009;&#x000b1;&#x02009;32.0. The patients were randomized into two groups of treatment lasting 6&#x000a0;weeks each. The dialysis sessions checked were the midweek sessions and the blood was drawn at times 0, 120&#x02019; and 240&#x02019;. Kappa (k) and lambda (&#x003bb;) light chain levels, &#x003b2;2microglobulin (&#x003b2;2M), C reactive protein (CRP) and albumin were checked.</p></sec><sec><title>Results</title><p>K light chain levels were 345.0&#x02009;&#x000b1;&#x02009;100.0&#x000a0;mg/L, &#x003bb; light chains were 121.4&#x02009;&#x000b1;&#x02009;27.0&#x000a0;mg/L. The values of k light chains at times 120&#x02019; and 240&#x02019; were significantly lower with PMMA and HFR17 than those obtained with F7. The reduction ratio per session (RRs) for k light chains was 44.1&#x02009;&#x000b1;&#x02009;4.3% with HFR17, 55.3&#x02009;&#x000b1;&#x02009;3.4% with PMMA, 25.7&#x02009;&#x000b1;&#x02009;8.3% with F7 (<italic>p</italic>&#x02009;=&#x02009;0.018). The RRs for &#x003bb; light chains was 30.3&#x02009;&#x000b1;&#x02009;2.9% with HFR17, 37.8&#x02009;&#x000b1;&#x02009;17.3% with PMMA, 14.0&#x02009;&#x000b1;&#x02009;3.9% with F7 (<italic>p</italic>&#x02009;=&#x02009;0.032). As to &#x003b2;2M, RRs was 42.4&#x02009;&#x000b1;&#x02009;3.2% with HFR17 vs. 33.9&#x02009;&#x000b1;&#x02009;2.8% with PMMA vs. 6.3&#x02009;&#x000b1;&#x02009;1.9% with F7 (<italic>p</italic>&#x02009;=&#x02009;0.022). The three filters tested showed no differences in CRP or albumin levels.</p></sec><sec><title>Conclusion</title><p>In terms of light chain and &#x003b2;2M removal, the PMMA and on-line HFR filters are similar and both are significantly more effective than the F7 filter in chronic dialysis patients.</p></sec><sec><title>Trial registration</title><p>The present trial was registered retrospectively (<ext-link ext-link-type="uri" xlink:href="https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S0006O5Q&#x00026;selectaction=Edit&#x00026;uid=U0003CCS&#x00026;ts=3&#x00026;cx=abq2ay">NCT02950389</ext-link>, 31/10/2016).</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>PMMA</kwd><kwd>On-line HFR</kwd><kwd>Free light chains</kwd><kwd>Toxins</kwd><kwd>Removal</kwd><kwd>Hemodialysis</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005969</institution-id><institution>Universit&#x000e0; di Bologna</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Immunoglobulin light chains are classified as middle molecule uremic toxins together with &#x003b2;2M and parathyroid hormone [<xref ref-type="bibr" rid="CR1">1</xref>]. They have a mean molecular weight of 25,000 daltons for monomers (k free light chains) and approximately 50,000 daltons for dimers (&#x003bb; free light chains) [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p>Raised serum levels of polyclonal free light chains can impair neutrophil function in terms of: 1) inhibited chemotactic movement; 2) reduced activation of glucose uptake; 3) inhibited apoptosis [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p>Immunoglobulin light chains are able to interact with B lymphocyte membranes leading to the activation of transmembrane signaling [<xref ref-type="bibr" rid="CR2">2</xref>]. The ensuing impairment of neutrophil function can contribute to the chronic inflammation state of uremic patients and to the increased risk of bacterial infections [<xref ref-type="bibr" rid="CR2">2</xref>]. Desjardins et al. demonstrated an association between free light chain levels and vascular calcification progression in chronic kidney disease patients [<xref ref-type="bibr" rid="CR3">3</xref>]. Nonetheless, serum free light chains in patients with chronic kidney disease are associated with the risk of end stage renal disease and death [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p>It seems that high flux PMMA membranes significantly reduce the light chain level, presumably due to adsorption [<xref ref-type="bibr" rid="CR5">5</xref>]. This behavior has led to the use of PMMA in the removal of monoclonal free light chains during multiple myeloma [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p>Preliminary reports describe a significant reduction in free light chains also during hemodiafiltration with reinfusion of endogenous ultrafiltrate (on-line HFR) [<xref ref-type="bibr" rid="CR7">7</xref>]. A recent paper by Borrelli et al. reported an improvement in chronic inflammation after chronic online HFR in dialysis patients [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p>The aim of this crossover observational study was to compare free light chain removal by three different hemodialysis filters in a cohort of chronic dialysis patients not affected by multiple myeloma.</p></sec><sec id="Sec2"><title>Methods</title><p>One hundred and sixty-three patients on chronic hemodialysis at the Nephrology, Dialysis and Transplantation Unit of S.Orsola University Hospital in Bologna were considered for the study. The patients were enrolled between November 2013 and March 2015.</p><p>The inclusion criteria were free light chain values &#x0003e;100&#x000a0;mg/L for k chains and &#x0003e;50&#x000a0;mg/L for &#x003bb; chains. These levels were chosen arbitrarily because no cut-off levels are available in the literature for the assessment of lowered serum free light chain values during hemodialysis in patients with end-stage renal disease. Fifty-five patients who had light chain levels higher than those required by the inclusion criteria were selected. Among these, 35 patients were excluded: 21 for intradialytic hypotension during bicarbonate dialysis, six patients for multiple myeloma requiring the double PMMA filter application, five for poly-allergy, one for transferral to a peripheral dialysis facility, one for recovery of renal function and one for HIV positivity. Other inclusion criteria were: age &#x0003e;18&#x000a0;years, absence or &#x0003c;200&#x000a0;ml/die residual diuresis, fistula or central venous catheter with blood flow &#x0003e;250&#x000a0;ml/min. Finally 20 patients were enrolled. Patient characteristics are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The filters used during the study were: i) HFR17 (Bellco, Mirandola, Italy), a double chamber filter used for online HFR. The first part of the filter consisted in a polyphenylene high flux hemofilter with an ultrafiltration coefficient (Kuf) of 28&#x000a0;ml/h/mmHg, a surface area of 0.7&#x000a0;m<sup>2</sup> and a membrane cut-off value of 35,000 daltons. The endogenous ultrafiltrate rate is obtained automatically by means of the transmembrane pressure levels in the hemofilter. These are calculated from two pressure sensors: the first is on the arterial bubble chamber and the second before the roller pump of the ultrafiltrate. The ultrafiltrate is driven from this hemofilter to a 40&#x000a0;g neutral styrenic resin that allows an adsorbing area of 28,000&#x000a0;m<sup>2</sup>. After adsorption, the ultrafiltrate is added to the whole blood that, in turn, passes into the second HFR17 filter, a polyphenylene low flux filter (Kuf 13&#x000a0;ml/h/mmHg, surface area 1.7&#x000a0;m<sup>2</sup>) where the weight loss and diffusive depuration take place. ii) PMMA (Toray Filtryzer BK-F, Tokyo, Japan) with a surface area of 2.1&#x000a0;m<sup>2</sup>, a membrane cut-off value of 20,000 daltons and an ultrafiltration coefficient (Kuf) of 26&#x000a0;ml/h/mmHg. iii) A conventional polysulfone membrane (Fresenius F7HPS, Bad Homburg, Germany) with a cut-off of 11,500 daltons, a Kuf of 16&#x000a0;ml/h/mmHg and a surface area of 1.7&#x000a0;m<sup>2</sup> was used as a control dialyzer.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics of the patients enrolled</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Group A</th><th>Group B</th></tr></thead><tbody><tr><td>Age (years)</td><td>64.2&#x02009;&#x000b1;&#x02009;16.0</td><td>69.8&#x02009;&#x000b1;&#x02009;14.5</td></tr><tr><td>Gender (M/F)</td><td>7/3</td><td>6/4</td></tr><tr><td>Dialysis vintage (months)</td><td>24.5&#x02009;&#x000b1;&#x02009;30.3</td><td>27.2&#x02009;&#x000b1;&#x02009;33.2</td></tr><tr><td>Type of dialysis (HD/HDF)</td><td>6/4</td><td>7/3</td></tr><tr><td>Vascular access (CVC/AVF)</td><td>8/2</td><td>7/3</td></tr><tr><td>Kappa light chains (mg/L)</td><td>341.3&#x02009;&#x000b1;&#x02009;97.1</td><td>353.4&#x02009;&#x000b1;&#x02009;115.5</td></tr><tr><td>Lambda light chains (mg/L)</td><td>120.8&#x02009;&#x000b1;&#x02009;25.3</td><td>124.7&#x02009;&#x000b1;&#x02009;26.2</td></tr><tr><td>Serum proteins (g/dl)</td><td>5.9&#x02009;&#x000b1;&#x02009;1.1</td><td>6.4&#x02009;&#x000b1;&#x02009;0.7</td></tr><tr><td>Serum albumin (g/dl)</td><td>3.6&#x02009;&#x000b1;&#x02009;0.3</td><td>3.5&#x02009;&#x000b1;&#x02009;0.7</td></tr><tr><td colspan="3">Causes of end stage renal disease</td></tr><tr><td>&#x02003;- Nephroangiosclerosis<break/>&#x02003;- Type 2 diabetes<break/>&#x02003;- Vasculitis<break/>&#x02003;- Glomerulonephritis<break/>&#x02003;- Polycystic disease<break/>&#x02003;- Obstructive nephropathy<break/>&#x02003;- Type 1 diabetes<break/>&#x02003;- Type 1 oxalosis</td><td>4<break/>2<break/>3<break/>0<break/>1<break/>1<break/>0<break/>1</td><td>4<break/>1<break/>0<break/>2<break/>0<break/>0<break/>1<break/>0</td></tr></tbody></table></table-wrap>
</p><p>The patients enrolled were randomized into two groups of treatments lasting 6&#x000a0;weeks each (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Group A: 1st and 2nd weeks with bicarbonate dialysis and filter PMMA, 3rd and 4th weeks with filter HFR17, 5th and 6th weeks with bicarbonate dialysis filter F7. Group B: 1st and 2nd weeks with filter HFR17, 3rd and 4th weeks with bicarbonate dialysis and filter PMMA, 5th and 6th weeks with bicarbonate dialysis filter F7 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The dialysis sessions carried out during weeks 1, 3 and 5 were considered washout sessions between weeks 2, 4 and 6 when the assessment of &#x003bb; and k light chains, &#x003b2;2M, C reactive protein and albumin was scheduled. Week number 1 was the washout period between the usual dialytic treatment of the patients enrolled and the beginning of the study. The checking dialysis session was the midweek session and the blood was drawn on starting dialysis (time 0), at two hours (time 120&#x02019;) and at dialysis end (time 240&#x02019;). All the dialysis sessions lasted four hours. Mean blood flow was 310&#x02009;&#x000b1;&#x02009;30&#x000a0;ml/min, the mean ultrafiltration rate was 700&#x02009;&#x000b1;&#x02009;200&#x000a0;ml/h, during HFR the endogenous ultrafiltrate rate was 2.3&#x02009;&#x000b1;&#x02009;0.4&#x000a0;ml/h. Dialysate flow was 500&#x000a0;ml/min. Low molecular weight heparin enoxaparin (Clexane&#x000ae;, Sanofi, Milan Italy) was used for anticoagulation of the extracorporeal circuit. Doses of 2000&#x000a0;IU (patients &#x0003c;50&#x000a0;kg of body weight), 4000&#x000a0;IU (patients between 50 to 90&#x000a0;kg of body weight) or 6000&#x000a0;IU (patients &#x0003e;90&#x000a0;kg of body weight) were administered in a single bolus on starting dialysis. Fresenius 5008 and Bellco Flexya dialysis machines were used. The concentrations of k and &#x003bb; light chains and &#x003b2;2M were measured by nephelometry (kit Freelite k/lambda, The Binding Site Group Ltd., Birmingham, UK; IIMAGE/IMMAGE 800 Beckman Coulter instrument, Brea California USA, Beckman Coulter &#x003b2;2M kit). Normal values: k light chains 3.3 -19.9&#x000a0;mg/L, &#x003bb; light chains 5.7&#x02013;26.3&#x000a0;mg/L, &#x003b2;2M 0.7&#x02013;2&#x000a0;mg/L. Molecular weights: k light chains: 22,500 daltons; &#x003bb; light chains: 45,000 daltons; &#x003b2;2M: 11,818 daltons. The reference range for patients with normal kidney function was considered between 0.26 and 1.65 according to Bourguignon et al. [<xref ref-type="bibr" rid="CR9">9</xref>]. CRP concentration was measured by turbidimetry (CRPLX, Tina-quant C-Reactive-Protein; Roche/Hitachi 902 analyzer). CRP normal value&#x02009;&#x0003c;&#x02009;0.8&#x000a0;mg/dl, molecular weight 120,000 daltons. Albumin was assessed using the common laboratory method. The reduction rate per session (RRs) was calculated as follows [<xref ref-type="bibr" rid="CR10">10</xref>]:<fig id="Fig1"><label>Fig. 1</label><caption><p>Study design</p></caption><graphic xlink:href="12882_2016_405_Fig1_HTML" id="MO1"/></fig>
<fig id="Fig2"><label>Fig. 2</label><caption><p>k free light chain removal with the three dialyzers tested at times 120&#x02019; PMMA&#x02009;=&#x02009;HFR17&#x02009;&#x0003c;&#x02009;F7HPS and 240&#x02019; PMMA&#x02009;=&#x02009;HFR17&#x02009;&#x0003c;&#x02009;F7HPS</p></caption><graphic xlink:href="12882_2016_405_Fig2_HTML" id="MO2"/></fig>
<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{R}\mathrm{R}\mathrm{s} = \left({\mathrm{C}}_{\mathrm{pre}} - {\mathrm{C}}_{\mathrm{post}\hbox{-} \mathrm{corr}}\right)/\ {\mathrm{C}}_{\mathrm{pre}}\times 100 $$\end{document}</tex-math><mml:math id="M2"><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mspace width="0.25em"/><mml:mo>=</mml:mo><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:mspace width="0.25em"/><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mi mathvariant="normal">post</mml:mi><mml:mo>&#x02010;</mml:mo><mml:mi mathvariant="normal">corr</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo stretchy="true">/</mml:mo><mml:mspace width="0.25em"/><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:math><graphic xlink:href="12882_2016_405_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula>
</p><p>where C<sub>pre</sub> is the predialysis solute level, and C<sub>post-corr</sub> is the post-dialysis solute concentration. The values measured during dialysis were corrected for hemoconcentration due to the patient&#x02019;s weight loss assuming a unicompartimental behavior of light chains described by the following formula [<xref ref-type="bibr" rid="CR11">11</xref>]:<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ {\mathrm{C}}_{\mathrm{post}-\mathrm{corr}} = {\mathrm{C}}_{\mathrm{post}}/\ \left\{1 + \left[\Delta \mathrm{B}\mathrm{W}/\left(0.2\times {\mathrm{BW}}_{\mathrm{post}}\right)\right]\right\} $$\end{document}</tex-math><mml:math id="M4"><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mi mathvariant="normal">post</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi mathvariant="normal">corr</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mspace width="0.25em"/><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">post</mml:mi></mml:msub><mml:mo stretchy="true">/</mml:mo><mml:mspace width="0.25em"/><mml:mfenced close="}" open="{"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">W</mml:mi><mml:mo stretchy="true">/</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0.2</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">W</mml:mi></mml:mrow><mml:mi mathvariant="normal">post</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:math><graphic xlink:href="12882_2016_405_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula>
</p><p>where C<sub>post-corr</sub> is the post-dialysis solute concentration and C<sub>post-corr</sub> is the concentration of light chains corrected for the hemoconcentration, &#x00394;BW is the weight subtracted during dialysis, and BW is the body weight at the end of dialysis.</p><sec id="Sec3"><title>Statistical analyses</title><p>Statistical analysis was performed using SPSS statistical software. The data are presented as mean&#x02009;&#x000b1;&#x02009;standard error of the mean. The Shapiro-Wilk test, suitable for small populations, showed a non-normal distribution of the variables, for which the non-parametric Friedman test was used. The <italic>p</italic> value &#x0003c;0.05 was considered normal. The Wilcoxon Signed Rank Test was subsequently used to see which pairwise comparisons resulted statistically different. In addition, as a multiple comparison was done, we applied the Bonferroni correction, thereby setting a <italic>p</italic> value&#x02009;=&#x02009;0.05 / 3&#x02009;=&#x02009;0.0167. For each of the sampling times 0.120 and 240&#x000a0;min, we compared the results and the RRs obtained with the different filters (HFR17, PMMA, F7).</p></sec></sec><sec id="Sec4"><title>Results</title><p>HFR17 removal of free light chains was statistically significant between time 0&#x02019; (k: 361.6&#x02009;&#x000b1;&#x02009;100.7&#x000a0;mg/L; &#x003bb; 122.4&#x02009;&#x000b1;&#x02009;27.6&#x000a0;mg/L) and time 120&#x02019; (k: 233.6&#x02009;&#x000b1;&#x02009;68.8&#x000a0;mg/L; &#x003bb; 84.3&#x02009;&#x000b1;&#x02009;15.6&#x000a0;mg/L) for both k and &#x003bb; chains (p &#x0003c;0.001). K and &#x003bb; chain concentrations were reduced between times 120&#x02019; and 240&#x02019; but the value did not reach statistical significance (<italic>p</italic>&#x02009;=&#x02009;ns). HFR17 significantly reduced &#x003b2;2M values between time 0&#x02019; (38.4&#x02009;&#x000b1;&#x02009;6.0&#x000a0;mg/L) and time 120&#x02019; (23.9&#x02009;&#x000b1;&#x02009;3.6&#x000a0;mg/L) and between times 120&#x02019; and 240&#x02019; (at time 240&#x02019; &#x003b2;2M values were 21.6&#x02009;&#x000b1;&#x02009;4.1&#x000a0;mg/L) (<italic>p</italic>&#x02009;=&#x02009;0.04). CRP values did not exhibit statistically significant changes at the three times considered.</p><p>PMMA significantly reduced k and &#x003bb; chains between time 0&#x02019; (k: 429.4&#x02009;&#x000b1;&#x02009;110.3&#x000a0;mg/L; &#x003bb;: 120.1&#x02009;&#x000b1;&#x02009;19.9&#x000a0;mg/L) and time 120&#x02019; (k: 218.5&#x02009;&#x000b1;&#x02009;62.2&#x000a0;mg/L; &#x003bb;: 72.2&#x02009;&#x000b1;&#x02009;14.3&#x000a0;mg/L) (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), but no significant reduction was found (<italic>p</italic>&#x02009;=&#x02009;ns) between time 120&#x02019; and time 240&#x02019;. A significant reduction was found for &#x003b2;2M between time 0&#x02019; (39.3&#x02009;&#x000b1;&#x02009;5.4&#x000a0;mg/L) and time 120&#x02019; (27.3&#x02009;&#x000b1;&#x02009;4.0&#x000a0;mg/L) (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), but not between times 120&#x02019; and 240&#x02019; (<italic>p</italic>&#x02009;=&#x02009;ns).</p><p>The values obtained for the k light chains with the F7 filter showed a non-significant reduction during each time interval considered; the same behavior was found for &#x003bb; chains and &#x003b2;2M values.</p><p>By comparing the different filters used at the different checking times the following results were obtained (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>): k light chains levels at time 0&#x02019; did not differ among the three filters tested (<italic>p</italic>&#x02009;=&#x02009;ns). At time 120&#x02019; the three filters differed significantly with the PMMA filter showing the lowest value (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). At time 240&#x02019; the k light chains level were significantly lower with HFR17 and PMMA in comparison to F7 (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). No difference in &#x003bb; light chain levels was found among the three filters tested at times 0&#x02019;, 120&#x02019; and 240&#x02019; (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). B2M levels at time 0&#x02019; did not differ among the three filters tested. At time 120&#x02019;, &#x003b2;2M levels were lower with HFR17 and PMMA in comparison with F7 (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and at 240&#x02019; (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) when HFR17&#x003b2;2M levels seemed slightly lower than those of PMMA (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). CRP values at times 0&#x02019;, 120&#x02019; and 240&#x02019; did not differ among the three filters tested (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>&#x003bb; free light chain removal with the three dialyzers tested: no differences were found at the checking times considered</p></caption><graphic xlink:href="12882_2016_405_Fig3_HTML" id="MO3"/></fig>
<fig id="Fig4"><label>Fig. 4</label><caption><p>&#x003b2;2M removal with the three dialyzers tested at times 120&#x02019; PMMA&#x02009;=&#x02009;HFR17&#x02009;&#x0003c;&#x02009;F7HPS and 240&#x02019; PMMA&#x02009;=&#x02009;HFR17&#x02009;&#x0003c;&#x02009;F7HPS</p></caption><graphic xlink:href="12882_2016_405_Fig4_HTML" id="MO4"/></fig>
<fig id="Fig5"><label>Fig. 5</label><caption><p>CRP values with the three dialyzers tested at the checking times considered</p></caption><graphic xlink:href="12882_2016_405_Fig5_HTML" id="MO5"/></fig>
</p><p>Finally the RRs was measured for k and &#x003bb; light chains and &#x003b2;2M. For k light chains, RRs values were higher with HFR17 and with PMMA than those obtained with F7 (<italic>p</italic>&#x02009;=&#x02009;0.018). RRs of &#x003bb; light chains and of &#x003b2;2M showed the same behavior (<italic>p</italic>&#x02009;=&#x02009;0.032 and <italic>p</italic>&#x02009;=&#x02009;0.022 respectively) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>).<fig id="Fig6"><label>Fig. 6</label><caption><p>Comparison of the RRs obtained with the three dialyzers tested for k and &#x003bb; light chains and for &#x003b2;2M. PMMA&#x02009;=&#x02009;HFR17&#x02009;&#x0003e;&#x02009;F7HPS</p></caption><graphic xlink:href="12882_2016_405_Fig6_HTML" id="MO6"/></fig>
</p><p>Predialysis and postdialysis k/&#x003bb; ratio values with the three dialyzers tested are showed in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>. After dialysis, the frequency of patients with a k/&#x003bb; ratio in the normal range described for subjects with normal kidney function was 60% (12/20) with HFR17, 55% (11/20) with PMMA and 40%(8/20) with F7 (<italic>p</italic>&#x02009;=&#x02009;ns).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Ratio k/l light chains before (time 0) and after dialysis (time 240&#x02019;)</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>HFR 17</th><th>PMMA</th><th>F7</th><th>P</th></tr></thead><tbody><tr><td colspan="5">Ratio k/l light chains</td></tr><tr><td>&#x02003;-time 0</td><td>7.7&#x02009;&#x000b1;&#x02009;4.2</td><td>8.9&#x02009;&#x000b1;&#x02009;4.7</td><td>10.6&#x02009;&#x000b1;&#x02009;6.1</td><td>ns</td></tr><tr><td>&#x02003;-time 240&#x02019;</td><td>4.8&#x02009;&#x000b1;&#x02009;2.2</td><td>6.8&#x02009;&#x000b1;&#x02009;3.6</td><td>14.3&#x02009;&#x000b1;&#x02009;10.4</td><td>0.02</td></tr><tr><td/><td>0.02</td><td>&#x0003c;0.001</td><td>ns</td><td/></tr></tbody></table></table-wrap>
<fig id="Fig7"><label>Fig. 7</label><caption><p>Effect of dialysis with HFR17, PMMA and F7 on k/&#x003bb; ratio before dialysis (time 0&#x02019;) and after dialysis (time 240&#x02019;). Dashed lines&#x02009;=&#x02009;normal reference range. Continuous lines&#x02009;=&#x02009;extended renal failure reference range [<xref ref-type="bibr" rid="CR9">9</xref>]</p></caption><graphic xlink:href="12882_2016_405_Fig7_HTML" id="MO7"/></fig>
</p><p>There was no difference in albumin levels among the three dialyzers tested. Using HFR17 albumin was 3.6&#x02009;&#x000b1;&#x02009;0.4&#x000a0;g/dl on starting dialysis vs. 3.7&#x02009;&#x000b1;&#x02009;0.7 at dialysis end (<italic>p</italic>&#x02009;=&#x02009;ns). With PMMA albumin values on starting dialysis were 3.6&#x02009;&#x000b1;&#x02009;0.4&#x000a0;g/dl vs. 3.6&#x02009;&#x000b1;&#x02009;0.7&#x000a0;g/dl at dialysis end (<italic>p</italic>&#x02009;=&#x02009;ns). Using the F7HPS dialyzer albumin was 3.6&#x02009;&#x000b1;&#x02009;0.4&#x000a0;g/dl on starting dialysis vs. 3.7&#x02009;&#x000b1;&#x02009;0.6&#x000a0;g/dl at dialysis end (<italic>p</italic>&#x02009;=&#x02009;ns). No difference among the three dialyzers was found comparing the values obtained with each filter at the checking times considered in the study.</p><p>Spearman&#x02019;s correlation test was used to evaluate any correlation between the blood flow rate during the single dialysis session and the k and &#x003bb; free chain concentration. The correlation coefficient for the PMMA dialyzer at 120&#x02019; was 0.056 (<italic>p</italic>&#x02009;=&#x02009;ns) for k light chains, -0.272 (<italic>p</italic>&#x02009;=&#x02009;ns) for &#x003bb; light chains. At dialysis end it was -0.161 (<italic>p</italic>&#x02009;=&#x02009;ns) for k light chains and -0.131 (<italic>p</italic>&#x02009;=&#x02009;ns) for &#x003bb; light chains. The correlation coefficient for HFR17 at 120&#x02019; was -0.483 (<italic>p</italic>&#x02009;=&#x02009;ns) for k light chains, -0.268 (<italic>p</italic>&#x02009;=&#x02009;ns) for &#x003bb; light chains. At dialysis end it was -0.161 (<italic>p</italic>&#x02009;=&#x02009;ns) for k light chains and -0.075 (<italic>p</italic>&#x02009;=&#x02009;ns) for &#x003bb; light chains.</p></sec><sec id="Sec5"><title>Discussion</title><p>The present study showed that the k light chains were significantly lower with HFR17 and PMMA dialyzers than with the F7 during a four-hour dialysis treatment. Free light chain removal had already approached a plateau at the second hour of dialysis with both PMMA and HFR17 filters. For both PMMA and HFR17 no further significant improvement in k and &#x003bb; light chains was found in the second part of the dialysis sessions. The RRs showed free k light chain removal was higher with PMMA than with the HFR17 or F7 dialyzers. &#x003bb; light chain removal peaked after two hours of dialysis treatment but without statistical differences among the three filters. This is probably explained by the small cohort of patients enrolled and by the low levels of &#x003bb; light chains considered suitable for the study at dialysis start. &#x003bb; free light chain removal seems to be more difficult due to the dimeric structure and higher molecular weight than k light chains [<xref ref-type="bibr" rid="CR12">12</xref>]. Nonetheless, PMMA showed significantly higher RRs for &#x003bb; free light chains than the HFR17 and F7 dialyzers. &#x003b2;2M removal at the second hour of treatment was already significantly lower with both HFR17 and PMMA than with the F7 dialyzer. The &#x003b2;2M RRs was significantly higher with both online HFR and PMMA in comparison with F7.</p><p>Many studies have sought to establish the optimal dialysis technique for free light chain removal during multiple myeloma with renal involvement. However, the issue of free light chains as uremic toxins in non-multiple myeloma patients has received only marginal attention [<xref ref-type="bibr" rid="CR2">2</xref>]. In the field of free light chain removal the PMMA membrane is the first choice technique since this membrane removes proteins not only via permeation but also via an adsorptive mechanism [<xref ref-type="bibr" rid="CR5">5</xref>]. In 2002, Cohen enrolled 71 non-myeloma chronic hemodialysis patients treated with bicarbonate dialysis and 33 patients treated with hemodiafiltration [<xref ref-type="bibr" rid="CR13">13</xref>]. He tested free light chain removal by six different dialyzers in the group of patients treated with bicarbonate dialysis, and three dialyzers in the group of patients who underwent hemodiafiltration. Free light chains, namely &#x003bb; free light chains, were significantly reduced only with the PMMA dialyzer. The removal rate considered two hours after dialysis start was 43% for &#x003bb; free light chains and 12% for the k free light chains. Unfortunately only four patients underwent PMMA hemodialysis while four patients underwent PMMA hemodiafiltration [<xref ref-type="bibr" rid="CR13">13</xref>]. Fabbrini et al. carried out a retrospective study on ten acute and chronic dialysis patients with high free light chain levels (k or &#x003bb;&#x02009;&#x0003e;&#x02009;500&#x000a0;mg/dl). Five patients underwent bicarbonate dialysis with a single PMMA filter and the other five patients with the &#x0201c;enhancing adsorption properties technique&#x0201d; (EAD) [<xref ref-type="bibr" rid="CR14">14</xref>]. With EAD the PMMA dialyzer is replaced after two hours of dialysis treatment. The five single PMMA filter patients showed free light chain RRs corresponding to 22.3% for k light chains and 21% for &#x003bb; light chains after four hours of treatment. The five patients who underwent EAD showed RRs of 31% for k free light chains and 53.1% for &#x003bb; free light chains [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p>Testa et al. enrolled 11 chronic hemodialysis patients undergoing online HFR, finding a significant reduction of k and &#x003bb; free light chains with the HFR17 dialyzer. The mean reduction of k light chains was 30% and 20% for &#x003bb; free light chains [<xref ref-type="bibr" rid="CR7">7</xref>]. The removal of free light chains during online HFR depends on the adsorption obtained by the resin cartridge of the HFR17 filter. This was confirmed by an in vitro experiment where 10&#x000a0;ml of styrenic neutral resin were incubated with the serum of patients with IgA-k and IgG-k multiple myeloma. The serum monoclonal protein was significantly reduced, but unfortunately their study did not include a control group [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>A conventional polysulfone membrane like the F7 seems to allow some removal of free light chains by adsorption because its cut-off is about 11,000 daltons and it does not allow free light chain removal by diffusion or convection. Birk et al. observed that one type of polysulfone (Fresenius F60) showed a higher adsorption of both total proteins and low molecular weight proteins than another polysulfone membrane tested (D30) during an &#x0201c;in vitro&#x0201d; comparison of 11 different membrane materials [<xref ref-type="bibr" rid="CR15">15</xref>]. Interestingly, Lamy et al. enrolled 31 chronic hemodialysis patients in a prospective observational study evaluating the reduction of free light chain values with high-flux dialyzers like FX80 and FX100 [<xref ref-type="bibr" rid="CR15">15</xref>]. The RRs for k free light chains was 66% with online HDF vs. 52% with bicarbonate dialysis (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), whereas no difference was found between the two techniques tested for &#x003bb; free light chains (37% RRs with both techniques) [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p>Our study found no differences in CRP levels among the three dialyzers tested. CRP is considered a marker of intradialytic inflammatory activation and selective solute removal by the dialyzers tested [<xref ref-type="bibr" rid="CR17">17</xref>]. Another important issue during light chain removal is the albumin loss: filters with a high cut-off allow an albumin loss that can approach 63&#x000a0;g/session [<xref ref-type="bibr" rid="CR18">18</xref>]. No albumin loss was found during each session with the three dialyzers tested confirming the selectivity of the adsorption. This was due to the low cut-off value of the PMMA and F7 dialyzers and to reinfusion of the endogenous ultrafiltrate after adsorption obtained with the neutral resin of the HFR17 dialyzer into the whole blood returned to the patient.</p><p>The main weaknesses of this study are the small cohort of patients enrolled, the low levels of &#x003bb; light chains considered suitable for the study at dialysis start and the limited number of biomarkers considered. Conversely, one of the strengths of the study is its crossover study design, which allows each patient to be his/ her control, strongly reducing the variability among patients. Other strengths are the randomization of the patients into two groups and the washout periods between the experimental phases with each filter tested, reducing the carryover effect of the previous filter / hemodialysis technique used.</p></sec><sec id="Sec6"><title>Conclusions</title><p>Our study yielded some important results for everyday clinical practice. Firstly, the routine use of PMMA and HFR17 filters can significantly reduce the burden of free light chains and &#x003b2;2M in chronic dialysis patients not affected by multiple myeloma. PMMA was more effective in removing free light chains, while HFR17 proved more effective in the removal of &#x003b2;2M [<xref ref-type="bibr" rid="CR19">19</xref>]. Secondly, this efficacy allows the chronic use of the two dialyzers in chronic dialysis patients when the recovery of multiple myeloma is obtained but not the recovery of renal failure. In this case, use of two PMMA filters for each dialysis session or use of the HFR-Supra is not indicated because of the low light chain values [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Thirdly, the polysulfone membrane showed a surprising intrinsic adsorptive ability, recently improved by the technical evolution of this membrane as in the case of polyethersulfone and polyester polymer alloy membrane filters [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. The depurative efficiency of the dialyzers tested on the middle molecules considered should encourage new studies with more patients to confirm these results on a large number of uremic toxins in the middle molecule range.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>BW</term><def><p>Body weight at the end of dialysis</p></def></def-item><def-item><term>C<sub>post</sub></term><def><p>The post-dialysis solute concentration</p></def></def-item><def-item><term>C<sub>post-corr</sub></term><def><p>The concentration of light chains corrected for the hemoconcentration</p></def></def-item><def-item><term>C<sub>pre</sub></term><def><p>The predialysis solute level</p></def></def-item><def-item><term>CRP</term><def><p>C reactive protein</p></def></def-item><def-item><term>EAD</term><def><p>Enhancing adsorption properties technique</p></def></def-item><def-item><term>g</term><def><p>Grams</p></def></def-item><def-item><term>k</term><def><p>Kappa</p></def></def-item><def-item><term>Kuf</term><def><p>Coefficient of ultrafiltration</p></def></def-item><def-item><term>online HDF</term><def><p>Online hemodiafiltration</p></def></def-item><def-item><term>online HFR</term><def><p>Hemodiafiltration with reinfusion of the endogenous ultrafiltrate</p></def></def-item><def-item><term>PMMA</term><def><p>Polymethylmethacrylate</p></def></def-item><def-item><term>RRs</term><def><p>Reduction rate per session</p></def></def-item><def-item><term>&#x003b2;2M</term><def><p>&#x003b2;2microglobulin</p></def></def-item><def-item><term>&#x00394;BW</term><def><p>The weight subtracted during dialysis</p></def></def-item><def-item><term>&#x003bb;</term><def><p>Lambda</p></def></def-item></def-list></glossary><ack><title>Acknowledgment</title><p>None.</p><sec id="FPar1"><title>Funding</title><p>This research was supported by a grant from the University of Bologna, which regards the expenses for the manuscript publication. Project entitled: &#x0201c;Ricerca fondamentale orientata&#x0201d;. Principal investigator: Gaetano La Manna.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>All data generated or analyzed during this study are included in this published article. The datasets analyzed during the current study are available from the corresponding author on reasonable request.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>GD: study design, data analysis, drafting the article. MIM: critical revision of the paper, data collection. OB: data collection, drafting the article. AS: drafting the article, data collection. IC: drafting the article. GC: data collection. AM: statistics, data analysis. MS: data analysis. RM: critical revision of the paper. GLM: critical revision of the paper and approval of the article. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Authors&#x02019; information</title><p>Gabriele Donati, M.D., Ph.D. is an attending physician at the Nephrology Dialysis and Transplantation Unit, S.Orsola University Hospital, Bologna Italy.</p><p>Maria Ilaria Moretti, M.D. graduated in Nephrology at the Nephrology Dialysis and Transplantation Unit, S.Orsola University Hospital, Bologna Italy.</p><p>Olga Baraldi, M.D., Ph.D is an attending physician at the Nephrology Dialysis and Transplantation Unit, S.Orsola University Hospital, Bologna Italy.</p><p>Alessandra Spazzoli, M.D. is a resident in Nephrology at the Nephrology Dialysis and Transplantation Unit, S.Orsola University Hospital, Bologna Italy.</p><p>Irene Capelli, M.D., Ph.D. is an attending physician at the Nephrology Dialysis and Transplantation Unit, S.Orsola University Hospital, Bologna Italy.</p><p>Giorgia Comai, M.D., Ph.D. is an attending physician at the Nephrology Dialysis and Transplantation Unit, S.Orsola University Hospital, Bologna Italy.</p><p>Antonio Marchetti, B.Sc is an attending biostatistician at the Department of Medicine and Public Health, University of Bologna, Italy.</p><p>Maria Sarma, M.D. is an attending physician at the Central Laboratory, S.Orsola University Hospital, Bologna Italy.</p><p>Rita Mancini, B.Sc. is the director of the Central Laboratory, S.Orsola University Hospital, Bologna Italy.</p><p>Gaetano La Manna, M.D., Ph.D. is an associate Professor of Nephrology at the University of Bologna and director of the Nephrology Dialysis and Transplantation Unit, S.Orsola University Hospital, Bologna Italy.</p></sec><sec id="FPar5"><title>Competing interest</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Consent for publication</title><p>Each patient gave his/her consent to publish the individual results obtained.</p></sec><sec id="FPar7"><title>Ethics approval and consent to participate</title><p>The study was approved by our institutional ethics committee &#x0201c;Comitato Etico&#x0201d;. Each patient gave his/her consent to participate in the study and to publish the results obtained.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanholder</surname><given-names>R</given-names></name><name><surname>De Smet</surname><given-names>R</given-names></name><name><surname>Glorieux</surname><given-names>G</given-names></name><etal/></person-group><article-title>Review on uremic toxins: classification, concentration, and interindividual variability</article-title><source>Kidney Int</source><year>2003</year><volume>63</volume><fpage>1934</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2003.00924.x</pub-id><pub-id pub-id-type="pmid">12675874</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>G</given-names></name></person-group><article-title>Immunoglobulin light chains in uremia</article-title><source>Kidney Int</source><year>2003</year><volume>84</volume><fpage>S15</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.63.s84.8.x</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desjardins</surname><given-names>L</given-names></name><name><surname>Liabeuf</surname><given-names>S</given-names></name><name><surname>Lenglet</surname><given-names>A</given-names></name><etal/></person-group><article-title>Association between free light chains levels, and disease progression and mortality in chronic kidney disease</article-title><source>Toxins</source><year>2013</year><volume>5</volume><issue>11</issue><fpage>2058</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.3390/toxins5112058</pub-id><pub-id pub-id-type="pmid">24217396</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayenes</surname><given-names>R</given-names></name><name><surname>Hutchison</surname><given-names>CA</given-names></name><name><surname>Emberson</surname><given-names>J</given-names></name><etal/></person-group><article-title>Serum free light chains and the risk of ESRD and death in CKD</article-title><source>Clin J Am Soc Nephrol</source><year>2011</year><volume>6</volume><issue>12</issue><fpage>2829</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.2215/CJN.03350411</pub-id><pub-id pub-id-type="pmid">22034503</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aoike</surname><given-names>I</given-names></name></person-group><article-title>Clinical significance of protein absorbable membranes - long-term clinical effects and analysis using a proteomic technique</article-title><source>Nephrol Dial Transplant</source><year>2007</year><volume>22</volume><issue>suppl 5</issue><fpage>13</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfm295</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutchison</surname><given-names>CA</given-names></name><name><surname>Blad&#x000e9;</surname><given-names>J</given-names></name><name><surname>Cockwell</surname><given-names>P</given-names></name><etal/></person-group><article-title>Novel approaches for reducing free light chains in patients with myeloma kidney</article-title><source>Nat Rev Nephrol</source><year>2012</year><volume>21: 8</volume><issue>4</issue><fpage>234</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2012.14</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Testa</surname><given-names>A</given-names></name><name><surname>Dejoie</surname><given-names>T</given-names></name><name><surname>Lecarrer</surname><given-names>D</given-names></name><etal/></person-group><article-title>Reduction of free immunoglobulin light chains using adsorption properties of hemodiafiltration with endogenous reinfusion</article-title><source>Blood Purif</source><year>2010</year><volume>30</volume><fpage>34</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1159/000316684</pub-id><pub-id pub-id-type="pmid">20588010</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrelli</surname><given-names>S</given-names></name><name><surname>Minutolo</surname><given-names>R</given-names></name><name><surname>De Nicola</surname><given-names>L</given-names></name><etal/></person-group><article-title>Effect of hemodiafiltration with endogenous reinfusion on overt idiopathic chronic inflammation in maintenance hemodialysis patients: a multicenter longitudinal study</article-title><source>Hemodial Int</source><year>2014</year><volume>18</volume><issue>4</issue><fpage>758</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1111/hdi.12178</pub-id><pub-id pub-id-type="pmid">24865622</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourguignon</surname><given-names>C</given-names></name><name><surname>Chenine</surname><given-names>L</given-names></name><name><surname>Bargnoux</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Hemodiafiltration improves free light chains and normalized k/&#x003bb; ratio in hemodialysis patients</article-title><source>J Nephrol</source><year>2016</year><volume>29</volume><fpage>251</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/s40620-015-0207-z</pub-id><pub-id pub-id-type="pmid">26022721</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donati</surname><given-names>G</given-names></name><name><surname>La Manna</surname><given-names>G</given-names></name><name><surname>Cianciolo</surname><given-names>G</given-names></name><etal/></person-group><article-title>Extracorporeal detoxification for hepatic failure using molecular adsorbent recirculating system: depurative efficiency and clinical results in a long-term follow-up</article-title><source>Artif Organs</source><year>2014</year><volume>38</volume><fpage>125</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1111/aor.12106</pub-id><pub-id pub-id-type="pmid">23834711</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergstr&#x000f6;m</surname><given-names>J</given-names></name><name><surname>Wehle</surname><given-names>B</given-names></name></person-group><article-title>No change in corrected &#x003b2;2 microglobulin concentration after cuprophane haemodialysis</article-title><source>Lancet</source><year>1987</year><volume>1</volume><issue>8533</issue><fpage>628</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(87)90266-2</pub-id><pub-id pub-id-type="pmid">2881162</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname><given-names>S</given-names></name><name><surname>Provot</surname><given-names>F</given-names></name><name><surname>Beuscart</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Aggregated serum free light chains may prevent adequate removal by high cut-off haemodialysis</article-title><source>Nephrol Dial Transplant</source><year>2011</year><volume>26</volume><fpage>1438</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfr019</pub-id><pub-id pub-id-type="pmid">21406545</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>G</given-names></name><name><surname>Rudnicki</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effect of dialysis on serum-plasma levels of free immunoglobulin light chains in end-stage renal disease patients</article-title><source>Nephrol Dial Transplant</source><year>2002</year><volume>17</volume><issue>5</issue><fpage>879</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1093/ndt/17.5.879</pub-id><pub-id pub-id-type="pmid">11981077</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabbrini</surname><given-names>P</given-names></name><name><surname>Sirtori</surname><given-names>S</given-names></name><name><surname>Casiraghi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Polymethylmethacrylate membrane and serum free light chains removal: enhancing adsorption properties</article-title><source>Blood Purif</source><year>2013</year><volume>35</volume><issue>suppl 2</issue><fpage>52</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1159/000350849</pub-id><pub-id pub-id-type="pmid">23676837</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birk</surname><given-names>HW</given-names></name><name><surname>Kistner</surname><given-names>A</given-names></name><name><surname>Wizemann</surname><given-names>W</given-names></name><name><surname>Sch&#x000fc;tterle</surname><given-names>G</given-names></name></person-group><article-title>Protein adsorption by artificial membrane materials under filtration conditions</article-title><source>Artif Organs</source><year>1995</year><volume>19</volume><issue>5</issue><fpage>411</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1111/j.1525-1594.1995.tb02351.x</pub-id><pub-id pub-id-type="pmid">7625919</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamy</surname><given-names>T</given-names></name><name><surname>Henri</surname><given-names>P</given-names></name><name><surname>Lobbedez</surname><given-names>T</given-names></name><etal/></person-group><article-title>Comparison between On-line high-efficiency hemodiafiltration and conventional high-flux hemodialysis for polyclonal free light chain removal</article-title><source>Blood Purif</source><year>2014</year><volume>37</volume><issue>2</issue><fpage>93</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1159/000357968</pub-id><pub-id pub-id-type="pmid">24603634</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefoni</surname><given-names>S</given-names></name><name><surname>Col&#x000ec;</surname><given-names>L</given-names></name><name><surname>Cianciolo</surname><given-names>G</given-names></name><etal/></person-group><article-title>Inflammatory response of a new synthetic dialyzer membrane. A randomized crossover comparison between polysulfone and helixone</article-title><source>Int J Artif Organs</source><year>2003</year><volume>26</volume><issue>1</issue><fpage>26</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">12602466</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rousseau-Gagnon</surname><given-names>M</given-names></name><name><surname>Agharazii</surname><given-names>M</given-names></name><name><surname>De Serres</surname><given-names>SA</given-names></name><name><surname>Desmeules</surname><given-names>S</given-names></name></person-group><article-title>Effectiveness of haemodiafiltration with heat sterilized high-flux polyphenylene HF dialyzer in reducing free light chains in patients with myeloma cast nephropathy</article-title><source>Plos One</source><year>2015</year><volume>10</volume><issue>10</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0140463</pub-id><pub-id pub-id-type="pmid">26466100</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cianciolo</surname><given-names>G</given-names></name><name><surname>Col&#x000ed;</surname><given-names>L</given-names></name><name><surname>La Manna</surname><given-names>G</given-names></name><etal/></person-group><article-title>Is beta2-microglobulin-related amyloidosis of hemodialysis patients a multifactorial disease? A new pathogenetic approach</article-title><source>Int J Artif Organs</source><year>2007</year><volume>30</volume><issue>10</issue><fpage>864</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">17992647</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Grazia</surname><given-names>M</given-names></name><name><surname>Mancini</surname><given-names>E</given-names></name></person-group><article-title>The double polymethylmetacrylate filter (Delete System) in the removal of light chains in chronic dialysis patients with multiple myeloma</article-title><source>Blood Purif</source><year>2013</year><volume>35</volume><issue>suppl 2</issue><fpage>5</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1159/000350837</pub-id><pub-id pub-id-type="pmid">23676829</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasquali</surname><given-names>S</given-names></name><name><surname>Ianuzzella</surname><given-names>F</given-names></name><name><surname>Corradini</surname><given-names>M</given-names></name><etal/></person-group><article-title>A novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR)</article-title><source>J Nephrol</source><year>2015</year><volume>28</volume><fpage>251</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1007/s40620-014-0130-8</pub-id><pub-id pub-id-type="pmid">25149172</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machiguchi</surname><given-names>T</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>H</given-names></name></person-group><article-title>Efficacy of haemodiafiltration treatment with PEPA dialysis membranes in plasma free light chain removal in a patient with primary amyloidosis</article-title><source>Nephrol Dial Transplant</source><year>2002</year><volume>17</volume><issue>9</issue><fpage>1689</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1093/ndt/17.9.1689</pub-id><pub-id pub-id-type="pmid">12198225</pub-id></element-citation></ref></ref-list></back></article>